Polyphron
An AI-guided tissue-engineering platform that grows human micro-tissues and models their responses to support drug research and development.
$20MSeed
LeadQC
Quiet Capital
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
Quiet Capital is the venture firm named by RWX and Thatch in their financing announcements.
Recorded funding activity
RWX supplies cloud environments for testing agent-developed software. Thatch manages employee-directed health benefits, while Polyphron develops micro-tissue models for drug research. The company histories preserve these distinct applications.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $785M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionNewLimit
NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease.
$435MSeries C
ParticipantScience Corporation
Develops brain-computer interface retinal implants to restore vision in patients with retinal diseases
$230MSeries C
Role not disclosedLoyal
Loyal develops medicines intended to extend dogs’ lifespans.
$100MSeries C
Role not disclosed